Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn’s Disease Strictures Ex Vivo
Open Access
- 18 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (2) , 332-345
Abstract
Crohn’s disease (CD) is a chronic bowel inflammation that ultimately leads to fibrosis, for which medical therapy is currently unavailable. Fibrotic strictures in CD are characterized by excessive extracellular matrix (ECM) deposition, altered balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), and overexpression of fibroblast activation protein (FAP), a marker of active fibroblasts. Here we investigated the role of FAP-targeted therapy in ECM remodeling in CD strictures ex vivo. Bowel specimens were obtained from stenotic and nonstenotic ileal segments from 30 patients with fibrostenotic CD undergoing surgery. FAP expression was evaluated in isolated mucosal myofibroblasts by immunoblotting and flow cytometry. Bowel tissue cultures were treated with anti-FAP antibody, and soluble collagen, TIMP-1, and MMPs were measured in tissue culture supernatants by immunoblotting. Anti-FAP-treated myofibroblasts were analyzed for TIMP-1 expression by immunoblotting, for migratory potential by wound healing assay, and for apoptosis by Annexin V staining. Myofibroblasts from stenotic CD mucosa showed upregulation of FAP expression when compared with nonstenotic mucosa. Treatment of stenotic tissues with anti-FAP antibody induced a dose-dependent decrease in collagen production, particularly affecting type I collagen. The treatment also reduced TIMP-1 production in CD strictures, without altering MMP-3 and MMP-12 secretion. Accordingly, anti-FAP treatment inhibited TIMP-1 expression in stenotic CD myofibroblasts and enhanced myofibroblast migration without affecting survival. FAP inhibition reduced type I collagen and TIMP-1 production by CD strictures ex vivo without compromising uninvolved bowel areas. These results suggest that targeting FAP could reconstitute ECM homeostasis in fibrostenotic CD.Keywords
This publication has 54 references indexed in Scilit:
- The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosisFibrogenesis & Tissue Repair, 2013
- Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNFEMBO Molecular Medicine, 2013
- Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasiaLaboratory Investigation, 2012
- The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid CellsImmunity, 2012
- Surgery for Crohn’s disease in the era of biologicals: A reduced need or delayed verdict?World Journal of Gastroenterology, 2012
- Fibroblasts and myofibroblasts in wound healing: Force generation and measurementJournal of Tissue Viability, 2011
- Correlation of MMP-3 and MMP-9 with Crohn’s Disease Activity in ChildrenDigestive Diseases and Sciences, 2011
- FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cellsBMC Cancer, 2011
- A practical guide to evaluating colocalization in biological microscopyAmerican Journal of Physiology-Cell Physiology, 2011
- The biology of Stat4 and Stat6Oncogene, 2000